IJU case reports · 2026
Pituitary Apoplexy Following Gonadotropin-Releasing Hormone Agonist Administration for Prostate Cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fujimura Masaaki, Shimizu Takahiro, Sakamoto Shinichi, Sato Hiroaki, Suzuki Hiroyoshi, Mikami Kazuo
Аннотация
INTRODUCTION: Pituitary apoplexy represents an uncommon endocrine emergency with potentially life-threatening consequences. Gonadotropin-releasing hormone agonist used for prostate cancer has the potential to induce pituitary apoplexy, particularly in the setting of a preexisting pituitary adenoma.
CASE PRESENTATION: A 76-year-old male with prostate cancer initially chose active surveillance; however, prostate-specific antigen (PSA) elevation required hormonal therapy 5 years later. A pancreatic islet tumor had been previously identified; however, its details were unavailable. He was presented to the emergency department 24 h after receiving the first gonadotropin-releasing hormone agonist injection. He showed severe headache, general fatigue, diplopia, and ptosis of the right eye. Brain MRI revealed a right deviated suprasellar pituitary adenoma with hemorrhagic infarction. He was conservatively treated with high-dose steroids; symptoms improved within 1 week.
CONCLUSION: Clinicians should be aware of the association of pituitary apoplexy with the use of gonadotropin-releasing hormone agonist and should ask about the patient's past history of multiple endocrine neoplasia (MEN).
CASE PRESENTATION: A 76-year-old male with prostate cancer initially chose active surveillance; however, prostate-specific antigen (PSA) elevation required hormonal therapy 5 years later. A pancreatic islet tumor had been previously identified; however, its details were unavailable. He was presented to the emergency department 24 h after receiving the first gonadotropin-releasing hormone agonist injection. He showed severe headache, general fatigue, diplopia, and ptosis of the right eye. Brain MRI revealed a right deviated suprasellar pituitary adenoma with hemorrhagic infarction. He was conservatively treated with high-dose steroids; symptoms improved within 1 week.
CONCLUSION: Clinicians should be aware of the association of pituitary apoplexy with the use of gonadotropin-releasing hormone agonist and should ask about the patient's past history of multiple endocrine neoplasia (MEN).